Post-Interleukin 17

Aus coViki
Version vom 12. April 2021, 15:22 Uhr von Ossip Groth (Diskussion | Beiträge)
(Unterschied) ← Nächstältere Version | Aktuelle Version (Unterschied) | Nächstjüngere Version → (Unterschied)
Wechseln zu: Navigation, Suche
PHA Biologicals

secukinumab, ixekizumab, brodalumab



32353597 ä. SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy
32358580 ä. COVID-19: a case for inhibiting IL-17?
32302707 ä. Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?: This paper is dedicated to Sofia Maione born during COVID-19 outbreak frisch geboren und schon publiziert...
32339777 2020. May IL-17 have a role in COVID-19 infection?
32504739 2020. Interleukin-17: A potential therapeutic target in COVID-19.
32475041 2020. Potential role of Anti-IL-17 in COVID-19 treatment.
32445955 2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"
32557955 2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.
32627226 2020. Potential role of IL-17 blocking agents in the treatment of severe COVID-19?
32651218 2020. A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge